MEK inhibitor trametinib in combination with gemcitabine regresses a patient-derived orthotopic xenograft (PDOX) pancreatic cancer nude mouse model-Reference-Cited by-同舟云学术

MEK inhibitor trametinib in combination with gemcitabine regresses a patient-derived orthotopic xenograft (PDOX) pancreatic cancer nude mouse model

Published:2018-06 Issue: Volume:52 Page:124-128
ISSN:0040-8166
Container-title:Tissue and Cell
language:en
Short-container-title:Tissue and Cell

Author:

Kawaguchi Kei,Igarashi Kentaro,Miyake Kentaro,Lwin Thinzar M.,Miyake Masuyo,Kiyuna Tasuku,Hwang Ho Kyoung,Murakami Takashi,Delong Jonathan C.,Singh Shree Ram,Clary Bryan,Bouvet Michael,Unno Michiaki,Hoffman Robert M.

Publisher

Elsevier BV

Subject

Cell Biology,Developmental Biology,General Medicine

Reference48 articles.

1. Facts & Figures 2018;American Cancer Society,2018

2. Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer;Chiorean;Br. J. Cancer,2016

3. Drug combination studies and their synergy quantification using the Chou-Talalay method;Chou;Cancer Res.,2010

4. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer;Conroy;N. Engl. J. Med.,2011

5. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer;Conroy;N Engl. J. Med.,2011

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An NFATc1/SMAD3/cJUN Complex Restricted to SMAD4-Deficient Pancreatic Cancer Guides Rational Therapies;Gastroenterology;2024-02

2. PAK4 inhibition significantly potentiates Gemcitabine activity in PDAC cells via inhibition of Wnt/β-catenin, p-ERK/MAPK and p-AKT/PI3K pathways;Biochemistry and Biophysics Reports;2023-09

3. Research progress in the establishment of pancreatic cancer models and preclinical applications;Cancer Innovation;2022-10

4. Prognostic Value, Immune Signature, and Molecular Mechanisms of the PHLDA Family in Pancreatic Adenocarcinoma;International Journal of Molecular Sciences;2022-09-07

5. Effective combinations of anti-cancer and targeted drugs for pancreatic cancer treatment;World Journal of Gastroenterology;2022-07-28